Global collaborations are advancing gene and cell therapies for rare diseases and cancer. The Abu Dhabi Department of Health, UCSF, and Innovative Genomics Institute partnered to build genome medicine centers integrating CRISPR-based technology for early diagnosis and treatment of rare genetic diseases. Separately, a Singaporean biotech received approval to start a Phase I/II trial for a potentially curative cell therapy for chronic Hepatitis B. These initiatives demonstrate momentum in translating gene editing and cell therapy advances into clinical applications with broad patient impact.